PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells
Linglong Yin(Central South University), Xiong Li(Central South University)
Cited by 126
Related Papers
The FOXM1–ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells
|Cell Death and Disease|2017|128
AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer
|Journal of Experimental & Clinical Cancer Research|2023|12